India Nears Breakthrough With First Single-Dose Dengue Vaccine “DengiAll”
New Delhi: Amid the rapidly rising cases of dengue across the globe, India is moving closer to a major medical breakthrough.
An indigenous dengue vaccine developed in the country has reached the final stage of clinical trials, raising hopes that it could become one of the world’s first single-dose vaccines capable of protecting people against this deadly mosquito-borne disease.
The vaccine, named DengiAll, is being developed by Indian pharmaceutical company Panacea Biotec under the supervision of the Indian Council of Medical Research (ICMR).
Scientists have been working on the vaccine for nearly 15 years, and it has now entered Phase-3 clinical trials, the final stage before potential regulatory approval.
If the trials prove successful, the vaccine could be launched as early as next year, offering a significant new tool in the fight against dengue.
Protection With Just One Injection
One of the most significant features of DengiAll is that it requires only a single dose. According to researchers, the vaccine is designed to protect against all four dengue virus serotypes, which has historically been one of the biggest scientific challenges in dengue vaccine development.
The vaccine is expected to be suitable for people between the ages of one and 60 years, making it potentially accessible to a much broader population than existing dengue vaccines.
Panacea Biotec’s Chief Scientific Officer, Dr. Syed Khalid Al, i said the company is working to bring the vaccine to the market at the earliest possible time.
Large-Scale Clinical Trials Underway
The Phase-3 trial currently underway involves more than 10,000 volunteers across India.
Participants are being randomly administered either the vaccine or a placebo (an inactive injection) as part of the study protocol. The results of the trial are expected to be available by the end of this year.
If the results confirm both safety and effectiveness, DengiAll could become the first dengue vaccine available in India and among the earliest single-dose dengue vaccines in the world.
Existing Vaccine Requires Two Doses
At present, the World Health Organization (WHO) recommends only one dengue vaccine globally — Qdenga. However, this vaccine is approved mainly for children between six and sixteen years of age and requires two doses administered three months apart. Moreover, Qdenga is not currently available in India.
In contrast, DengiAll is designed to cover a much wider age group and could simplify immunization with just one injection.
Dengue: A Growing Global Threat
According to the WHO, nearly half of the world’s population is now at risk of dengue infection. Each year, an estimated 100 to 400 million people are infected globally.
India alone has reported over one million dengue cases since 2021, with at least 1,500 deaths, highlighting the urgent need for effective preventive measures.
With dengue cases continuing to surge due to climate change, urbanization, and expanding mosquito habitats, the success of India’s indigenous vaccine could mark a major milestone in global public health.
If approved, DengiAll may not only protect millions in India but also offer a crucial solution for dengue-affected regions around the world.
#DengueVaccine #DengiAll #IndiaInnovation #PanaceaBiotec #ICMR #GlobalHealth #MosquitoBorneDiseases #PublicHealth #MedicalBreakthrough #DenguePrevention
